- Kane Biotech Inc. (KNE) receives positive results from biocompatibility and safety studies of DispersinB® in preparation for human clinical trials
- The wound gel is designed to accelerate healing of various dermal wounds and ulcers
- It showed to be safe, non-toxic, non-irritating, and passed all biocompatibility testing
- The studies and upcoming clinical trial are funded by a $2.7 million grant
- The funding supports developing DispersinB® into a potential treatment for biofilm-mediated antimicrobial resistance
- Kane Biotech Inc. (KNE) is up 13.64 per cent and is trading at $0.12 per share as of 11:41 a.m. ET.
Kane Biotech (KNE) received positive results from biocompatibility and in vivo safety studies of DispersinB® in preparation for human clinical trials.
DispersinB® wound gel is designed to accelerate healing of pressure ulcers, thickness wounds, diabetic foot and leg ulcers, post-surgical wounds, first and second-degree burns, and grafted and donor sites.
The gel underwent an extensive pre-clinical testing program which showed it to be safe, non-toxic, non-irritating and passed all biocompatibility testing. It also accelerated healing of infected and non-infected dermal wounds.
Marc Edwards, CEO of Kane Biotech, stated,
“Biofilm impaired healing is one of the largest unresolved problems in wound care… DispersinB® represents an important commercialization opportunity with the potential to help thousands of patients suffering from chronic wounds which can result in amputation, life-threatening sepsis, or loss of life.”
The studies and upcoming clinical trial are funded by a $2.7 million grant from the United States Department of Defense through the Medical Technology Enterprise Consortium.
The funding supports developing DispersinB® into a potential treatment for biofilm-mediated antimicrobial resistance in non-healing chronic wounds. Kane also received financial assistance from the Prairies Economic Development Canada’s Business Scale-up and Productivity program.
Kane Biotech Inc. (KNE) is up 13.64 per cent and is trading at $0.12 per share as of 11:41 a.m. ET.
